Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) EBITDA (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has disclosed EBITDA for 6 consecutive years, with -$19.9 million as the latest value for Q4 2020.

  • For Q4 2020, EBITDA fell 39.81% year-over-year to -$19.9 million; the TTM value through Dec 2020 reached -$71.4 million, down 24.13%, while the annual FY2025 figure was -$273.1 million, 19.6% up from the prior year.
  • EBITDA hit -$19.9 million in Q4 2020 for Syndax Pharmaceuticals, roughly flat from -$19.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$8.4 million in Q2 2016 and bottomed at -$19.9 million in Q4 2020.
  • Average EBITDA over 5 years is -$15.5 million, with a median of -$15.1 million recorded in 2017.
  • Year-over-year, EBITDA plummeted 157.1% in 2016 and then grew 26.52% in 2019.
  • Syndax Pharmaceuticals' EBITDA stood at -$11.1 million in 2016, then tumbled by 74.93% to -$19.5 million in 2017, then grew by 0.8% to -$19.3 million in 2018, then increased by 26.52% to -$14.2 million in 2019, then crashed by 39.81% to -$19.9 million in 2020.
  • According to Business Quant data, EBITDA over the past three periods came in at -$19.9 million, -$19.9 million, and -$16.6 million for Q4 2020, Q3 2020, and Q2 2020 respectively.